Cromolyn sodium salt
SIGMA/C0399 - ≥95%
Synonym: Cromoglycate; Cromoglycic acid
CAS Number: 15826-37-6
Empirical Formula (Hill Notation): C23H14Na2O11
Molecular Weight: 512.33
EC Number: 239-926-7
MDL Number: MFCD00057744
Linear Formula: C23H14O11Na2
Product Type: Chemical
| assay | ≥95% |
| form | powder |
| InChI | 1S/C23H16O11.Na.H/c24-11( |
| InChI key | UXMUBZWVLQEMRB-UHFFFAOYSA |
| originator | Sanofi Aventis |
| Quality Level | 200 ![]() |
| SMILES string | [Na].OC(COc1cccc2OC(=CC(= |
| Application: | Cromolyn sodium salt has been used to block mast cell activation and to inhibit histamine secretion from rodent peritoneal mast cells. It has also been used to stabilize mast cells. |
| Biochem/physiol Actions: | Cromolyn blocks the release of histamine and other pro-inflammatory mediators from mast cells. |
| Features and Benefits: | This compound was developed by Sanofi Aventis . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| General description: | Cromolyn sodium is a mast stabilizer, which is used to treat allergies. It is a bischromone and functions as a non-steroidal anti-inflammatory drug. It inhibits the release of histamines from mast cells. |
| Symbol | GHS07 |
| Signal word | Warning |
| Hazard statements | H315 - H319 - H335 |
| Precautionary statements | P302 + P352 - P305 + P351 + P338 |
| Hazard Codes | Xi |
| Risk Statements | 36/37/38 |
| Safety Statements | 26-36 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 2 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥95% |
| UNSPSC | 12352200 |


